ClinicalTrials.gg
CompletedNCT06145607Updated Mar 8, 2024

A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

A Phase 1 interventional study of ABBV-CLS-7262 in Healthy, sponsored by Calico Life Sciences LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Calico Life Sciences LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a randomized, three period, six sequence, single dose crossover design with ABBV-CLS-7262 in healthy adult subjects.

Read the detailed description

On Day 1 of each period, subjects will receive a single oral dose of ABBV-CLS-7262 administered according to the food regimen assigned. There will be a 4-day washout period between doses. Food regimens include administration after fasting, following a high-fat/high-calorie meal, or with apple sauce. Upon completion each subject will have taken a total of three doses of ABBV-CLS-7262, with one dose administered with each food regimen.

02

Conditions studied

  • Healthy

Keywords

  • Food effect
  • Pharmacokinetics
03

In context

Lead sponsor

Calico Life Sciences LLC is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult volunteers in general good health.
  • Must voluntarily sign and date an , approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures.
  • Individuals between 18 and 55 years of age inclusive at the time of screening.
  • (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2.
  • All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug.
  • All female subjects who are sexually active and of must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures
  • Pregnant or breastfeeding.
  • Treatment with any other treatment within 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Period 1, 2 and 3 ABBV-CLS-7262

    * Participants will receive ABBV-CLS-7262 administered under fasted conditions. * Participants will receive ABBV-CLS-7262 administered under fed conditions (high-fat/high-calorie breakfast). * Participants will receive ABBV-CLS-7262 administered with applesauce.

    Drug: ABBV-CLS-7262

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the pharmacokinetics following a single oral dose of ABBV-CLS-7262 taken with or without food.

    Maximum Plasma Concentration \[Cmax\]; Area under the Curve (AUC)

    Time frame: Approximately Two Weeks

  2. To assess the pharmacokinetics following a single oral dose of ABBV-CLS-7262 administered with or without applesauce.

    Maximum Plasma Concentration \[Cmax\]; Area under the Curve (AUC)

    Time frame: Approximately Two Weeks

Secondary outcomes

  1. Safety and Tolerability

    Number of patients with treatment-related adverse events as assessed by NCI CTCAE v4.03

    Time frame: Approximately Six Weeks

07

Study locations

1 site
  • AbbVie Clinical Pharmacology Research Unit (ACPRU)
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 24, 2023
StartActual
Dec 19, 2023
Primary completionActual
Jan 30, 2024
CompletionActual
Feb 26, 2024
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06145607
Lead sponsor
Calico Life Sciences LLC
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Nov 24, 2023
Start date
Dec 19, 2023
Primary completion
Jan 30, 2024
Completion
Feb 26, 2024
Last update
Mar 8, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosigotifator sodium tromethamine

Start the discussion